Glenmark Pharmaceuticals will host an analyst and institutional investor meeting on September 29, 2026, in Mumbai. The event is part of the PL Capital Emerging Titans 2026 Conference.

The company disclosed the schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will be conducted physically and will include both group and one-on-one sessions.

Meeting Details

Glenmark stated that no unpublished price-sensitive information is proposed to be shared during the interaction. The schedule may change due to exigencies on the part of the investor or the company.

Rashmi Khandelwal, Company Secretary and Compliance Officer, signed the disclosure filed with the National Stock Exchange of India Limited and BSE Limited.

Glenmark Pharmaceuticals shareholders approved the company's audited standalone and consolidated financial statements for FY26, alongside a final dividend of ₹2.50 per equity share. The 48th Annual General Meeting (AGM) concluded on September 11, 2026, with all resolutions passing by requisite majorities.

The meeting, held via Video Conferencing/Other Audio Visual Means (OAVM), saw participation from 54 shareholders. Mr. Glenn Saldanha, Chairman cum Managing Director & CEO, presided over the proceedings. He outlined the company's performance in FY25-26, highlighting innovation, commercial foundation strengthening, and quality growth.

Voting Results

Shareholders voted overwhelmingly in favor of the ordinary business resolutions. The adoption of the standalone financial statements received support from 99.92% of valid votes cast. Similarly, the consolidated financial statements were approved with 95.88% support.

The declaration of the final dividend garnered near-unanimous approval, with 99.99% of votes cast in favor. Only 490 shares voted against the dividend resolution out of more than 230 million shares participating.

Board Appointments and Auditors

Under special business, shareholders approved the reappointment of Mrs. Blanche Saldanha as a Non-Executive Director, liable to retire by rotation. This resolution passed with 99.77% of votes in favor.

The company also ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. This ordinary resolution received 99.99% support from voting members.

What the Numbers Show

The voting data indicates strong institutional and retail alignment on capital allocation and governance. The near-unanimous support for the dividend (99.99%) contrasts slightly with the consolidated financials approval (95.88%), where over 9.4 million shares voted against. This divergence suggests a segment of shareholders may have reservations regarding specific consolidated metrics or subsidiary performance, despite endorsing the parent entity's standalone results and payout policy.